NetraMark Signs New NetraAI Clinical Trial Analysis Agreement with Late-Stage Biopharmaceutical Company

About this update from Netramark Holdings Inc

TORONTO, June 29, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the "Company" or "NetraMark") (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), an artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today announced that it has signed a new agreement with a biopharmaceutical company developing a late-stage central nervous system therapy. Under the agreement, NetraMark will deploy its proprietary NetraAI platform to perform an in-depth analysis of patient-level data from a completed mid-to-late-stage clinical trial. The work will deliver actionable insights to optimize dose selection, enhance patient stratification, and inform critical future development decisions. In addition to dose response, the analysis is intended to generate insights related to treatment efficacy, safety, tolerability, cognition, functional outcomes, discontinuation patterns, and patient stratification. NetraMark's work is expected to support the new client's internal evaluation of its late-stage clinical development program. "This agreement marks another important commercial win and reflects the growing momentum behind NetraAI," said George Achilleos, Chief Executive Officer of NetraMark. "Our clients are increasingly recognizing that completed clinical trials often contain substantially more information than is captured through conventional analyses. Our proprietary and novel AI platform, NetraAI, is designed to identify clinically interpretable Model-Derived Subgroups, which are compact patient profiles, defined by a small number of variables that can explain dose response, safety, and treatment heterogeneity. These insights may help our clients optimize late-stage development programs and make more informed decisions before committing to major late-stage clinical investments." This agreement represents NetraMark's ninth booked commercial contract since the start of its current fiscal year in October 2025, further demonstrating growing adoption of NetraAI among biopharmaceutical sponsors for late-stage clinical development programs. The Company believes this contract further demonstrates growing interest in AI-enabled clinical trial analytics among biopharmaceutical sponsors. NetraMark will continue to pursue opportunities where its platform can support clinical development programs across CNS,...

View stock analysis, news, and events for Netramark Holdings Inc